Medtronic (MDT) Stock Forecast & Price Target

Compare

6,333 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MDT Analyst Ratings

Moderate Buy

10 Buy

10 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Medtronic

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MDT Stock 12 Month Forecast

Average Price Target

$111.94

▲(12.22% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Medtronic in the last 3 months. The average price target is $111.94 with a high forecast of $120.00 and a low forecast of $102.00. The average price target represents a 12.22% change from the last price of $99.75.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"77":"$77","88":"$88","99":"$99","110":"$110","121":"$121"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":111.94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$111.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":102,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$102.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[77,88,99,110,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.34,104.62153846153846,105.90307692307692,107.18461538461538,108.46615384615384,109.7476923076923,111.02923076923076,112.31076923076924,113.5923076923077,114.87384615384616,116.15538461538462,117.43692307692308,118.71846153846154,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.34,104.00153846153846,104.66307692307693,105.32461538461538,105.98615384615385,106.64769230769231,107.30923076923077,107.97076923076924,108.63230769230769,109.29384615384615,109.95538461538462,110.61692307692307,111.27846153846154,{"y":111.94,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.34,103.23692307692308,103.13384615384615,103.03076923076924,102.92769230769231,102.82461538461538,102.72153846153846,102.61846153846155,102.51538461538462,102.41230769230769,102.30923076923077,102.20615384615385,102.10307692307693,{"y":102,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":83.78,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.01,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.69,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.1,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.42,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.08,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.34,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$120.00

Average Price Target$111.94

Lowest Price Target$102.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joanne Wuensch

Citi

$117

Buy

17.29%

Upside

Reiterated

12/11/25

Citi Keeps Their Buy Rating on Medtronic (MDT)

Matthew O'Brien

Piper Sandler

$105

Hold

5.26%

Upside

Reiterated

12/11/25

Piper Sandler Reaffirms Their Hold Rating on Medtronic (MDT)

Christopher Pasquale

Nephron

$120

Buy

20.30%

Upside

Upgraded

12/08/25

Medtronic upgraded to Buy from Hold at Nephron ResearchMedtronic upgraded to Buy from Hold at Nephron Research

Travis Steed

Bank of America Securities

$115

Buy

15.29%

Upside

Reiterated

12/04/25

Analysts Offer Insights on Healthcare Companies: Cooper Co (NASDAQ: COO) and Medtronic (NYSE: MDT)We maintain our Buy rating on MDT, as we see the pipeline coming through and accelerating growth at a time when MDT is committed to delivering EPS leverage.

Josh Jennings

TD Cowen

$119

Buy

19.30%

Upside

Reiterated

12/04/25

Medtronic's Strategic Advancements and Early FDA Approval of Hugo Boost Buy RatingWe have already seen good data for Hugo in two other indications, hernia repair and gyn benign (hysterectomy). MDT recently began a US IDE trial in gyn that includes oncologic cases.

Brandon Vazquez

William Blair

―

Hold

―

Reiterated

12/04/25

Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (NASDAQ: PLRX), uniQure (NASDAQ: QURE) and Medtronic (NYSE: MDT)

Rick Wise

Stifel Nicolaus

$105

Hold

5.26%

Upside

Assigned

12/03/25

Medtronic's Cautious U.S. Market Entry with HUGO: Hold Rating Amid Uncertain ImpactWe rate Medtronic shares Hold. After multiple challenging post-Covid years, Medtronic is now more stable but still a “show-me” story. With the company’s revenue and earnings growth outlook below MedTech peers, new innovations are critical to improve the MDT growth setup. Specifically, the HUGO surgical robotic system, renal denervation hypertension treatment, and new diabetes innovations could be important growth drivers ahead. But, today, it is difficult to gauge when and how these innovations will begin to drive improving MDT performance. In light of MDT's mid-single-digit revenue growth outlook and high-single-digit earnings growth outlook, the stock appears reasonably valued relative to companies similar revenue growth and profitability growth profiles, in our view.

Ryan Zimmerman

BTIG

―

Hold

―

Reiterated

12/03/25

Medtronic's Strategic Moves and Market Position: Balancing Growth Prospects with Current ValuationWe also would note that given MDT's size and scale, we would not be surprised to see MDT bundle Hugo with other products to health systems in order to place more systems and drive utilization of instrumentation. Given the growing demand for leasing arrangements this may suit MDT well.

Richard Newitter

Truist Financial

$103→$110

Hold

10.28%

Upside

Reiterated

11/20/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: BrightSpring Health Services, Inc. (NASDAQ: BTSG), Medtronic (NYSE: MDT) and Vericel (NASDAQ: VCEL)

Matt Miksic

Barclays

$111

Buy

11.28%

Upside

Reiterated

11/20/25

Barclays Sticks to Its Buy Rating for Medtronic (MDT)

David Rescott

Robert W. Baird

$103→$109

Hold

9.27%

Upside

Reiterated

11/19/25

Medtronic price target raised to $109 from $103 at BairdMedtronic price target raised to $109 from $103 at Baird

Robbie Marcus

J.P. Morgan

$100→$105

Hold

5.26%

Upside

Reiterated

11/19/25

J.P. Morgan Sticks to Their Hold Rating for Medtronic (MDT)

Larry Biegelsen

Wells Fargo

$100→$114

Buy

14.29%

Upside

Reiterated

11/19/25

Medtronic price target raised to $114 from $100 at Wells FargoMedtronic price target raised to $114 from $100 at Wells Fargo

Danielle Antalffy

UBS

$95→$102

Hold

2.26%

Upside

Reiterated

11/19/25

Cautious Hold Rating on Medtronic Amid Mixed Segment Performance and Uncertain Growth Prospects

Lee Hambright

Bernstein

$98→$111

Buy

11.28%

Upside

Assigned

11/19/25

Bernstein Keeps Their Buy Rating on Medtronic (MDT)We rate Medtronic Outperform with a price target of $111 (up from $98) using a forward P/E multiple of 17.5x.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joanne Wuensch

Citi

$117

Buy

17.29%

Upside

Reiterated

12/11/25

Citi Keeps Their Buy Rating on Medtronic (MDT)

Matthew O'Brien

Piper Sandler

$105

Hold

5.26%

Upside

Reiterated

12/11/25

Piper Sandler Reaffirms Their Hold Rating on Medtronic (MDT)

Christopher Pasquale

Nephron

$120

Buy

20.30%

Upside

Upgraded

12/08/25

Medtronic upgraded to Buy from Hold at Nephron ResearchMedtronic upgraded to Buy from Hold at Nephron Research

Travis Steed

Bank of America Securities

$115

Buy

15.29%

Upside

Reiterated

12/04/25

Josh Jennings

TD Cowen

$119

Buy

19.30%

Upside

Reiterated

12/04/25

Brandon Vazquez

William Blair

―

Hold

―

Reiterated

12/04/25

Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (NASDAQ: PLRX), uniQure (NASDAQ: QURE) and Medtronic (NYSE: MDT)

Rick Wise

Stifel Nicolaus

$105

Hold

5.26%

Upside

Assigned

12/03/25

Ryan Zimmerman

BTIG

―

Hold

―

Reiterated

12/03/25

Richard Newitter

Truist Financial

$103→$110

Hold

10.28%

Upside

Reiterated

11/20/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: BrightSpring Health Services, Inc. (NASDAQ: BTSG), Medtronic (NYSE: MDT) and Vericel (NASDAQ: VCEL)

Matt Miksic

Barclays

$111

Buy

11.28%

Upside

Reiterated

11/20/25

Barclays Sticks to Its Buy Rating for Medtronic (MDT)

David Rescott

Robert W. Baird

$103→$109

Hold

9.27%

Upside

Reiterated

11/19/25

Medtronic price target raised to $109 from $103 at BairdMedtronic price target raised to $109 from $103 at Baird

Robbie Marcus

J.P. Morgan

$100→$105

Hold

5.26%

Upside

Reiterated

11/19/25

J.P. Morgan Sticks to Their Hold Rating for Medtronic (MDT)

Larry Biegelsen

Wells Fargo

$100→$114

Buy

14.29%

Upside

Reiterated

11/19/25

Medtronic price target raised to $114 from $100 at Wells FargoMedtronic price target raised to $114 from $100 at Wells Fargo

Danielle Antalffy

UBS

$95→$102

Hold

2.26%

Upside

Reiterated

11/19/25

Cautious Hold Rating on Medtronic Amid Mixed Segment Performance and Uncertain Growth Prospects

Lee Hambright

Bernstein

$98→$111

Buy

11.28%

Upside

Assigned

11/19/25

Bernstein Keeps Their Buy Rating on Medtronic (MDT)We rate Medtronic Outperform with a price target of $111 (up from $98) using a forward P/E multiple of 17.5x.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medtronic

1 Month

xxx

Success Rate

16/27 ratings generated profit

Average Return

+0.83%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 59.26% of your transactions generating a profit, with an average return of +0.83% per trade.

3 Months

xxx

Success Rate

17/22 ratings generated profit

Average Return

+4.58%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 77.27% of your transactions generating a profit, with an average return of +4.58% per trade.

1 Year

Larry BiegelsenWells Fargo

Success Rate

26/31 ratings generated profit

Average Return

+9.24%

reiterated a buy rating 24 days ago

Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 83.87% of your transactions generating a profit, with an average return of +9.24% per trade.

2 Years

xxx

Success Rate

26/29 ratings generated profit

Average Return

+15.11%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 89.66% of your transactions generating a profit, with an average return of +15.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDT Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MDT has received 32 Buy Ratings, 20 Hold Ratings, and 0 Sell Ratings. MDT average Analyst price target in the past 3 months is 111.94.

Each month's total comprises the sum of three months' worth of ratings.

MDT Financial Forecast

MDT Earnings Forecast

Next quarter’s earnings estimate for MDT is $1.34 with a range of $1.33 to $1.36. The previous quarter’s EPS was $1.36. MDT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MDT has Performed in-line its overall industry.

MDT Sales Forecast

Next quarter’s sales forecast for MDT is $8.91B with a range of $8.86B to $9.04B. The previous quarter’s sales results were $8.96B. MDT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MDT has Performed in-line its overall industry.

MDT Stock Forecast FAQ

What is MDT’s average 12-month price target, according to analysts?

Based on analyst ratings, Medtronic’s 12-month average price target is 111.94.

What is MDT’s upside potential, based on the analysts’ average price target?

Medtronic has 12.22% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MDT a Buy, Sell or Hold?

Medtronic has a consensus rating of Moderate Buy which is based on 10 buy ratings, 10 hold ratings and 0 sell ratings.

What is Medtronic’s price target?

The average price target for Medtronic is 111.94. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $102.00. The average price target represents 12.22% Increase from the current price of $99.75.

What do analysts say about Medtronic?

Medtronic’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of MDT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Medtronic (MDT) Stock Forecast & Price Target

MDT Analyst Ratings

MDT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Medtronic

MDT Analyst Recommendation Trends

MDT Financial Forecast

MDT Earnings Forecast

MDT Sales Forecast

MDT Stock Forecast FAQ

Detailed List of Analyst Forecasts